Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: Results of prospective study in nonrandomized population of 259 patients

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069321" target="_blank" >RIV/00216224:14110/13:00069321 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—

Jazyk výsledku
angličtina
Název v původním jazyce
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: Results of prospective study in nonrandomized population of 259 patients
Popis výsledku v původním jazyce
Background: The purpose was to evaluate the activity and feasibility of CBDCA together with NVBO in 1st line treatment NSCLC patients. Conclusions: The treatment with NVBO and CBDCA was well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology.
Název v anglickém jazyce
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: Results of prospective study in nonrandomized population of 259 patients
Popis výsledku anglicky
Background: The purpose was to evaluate the activity and feasibility of CBDCA together with NVBO in 1st line treatment NSCLC patients. Conclusions: The treatment with NVBO and CBDCA was well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology.

Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)